Dec 11, 2020 10:23am
Viatris restructuring efforts could impact up to 20% of its 45,000-strong workforce, putting up to 9,000 jobs on the line. (Pixabay)
A little less than a month after Pfizer s Upjohn unit and Mylan successfully merged to create generics business Viatris, the company is already looking at ways to slash costs.
Newly minted Viatris Friday laid out detailed plans for a global manufacturing initiative that could put thousands of jobs on the line. By 2024 at the latest, the company aims to wring at least $1 billion from its cost base, and it s planning to close, downsize or divest up to 15 facilities to meet that goal.
Dec 11, 2020 9:25am
Takeda and COVID-19 vaccines from Chinese firms Sinovac, Clover Biopharma and Sinopharm made our news this week. (Google)
Takeda s cytomegalovirus candidate, TAK-602, hit its phase 3 goal in transplant patients. The Japanese pharma s Iclusig posted new chronic myeloid leukemia data, touting five-year survival in 60% of patients. China-made COVID-19 vaccines had a busy week: Sinovac plans to double its COVID-19 capacity with a new, $515 million investment from Sino Biopharma; Clover Biopharma kicked off a pivotal trial of its S-Trimer vaccine paired with a GlaxoSmithKline adjuvant, and an inactivated shot from Sinopharm won approval in the United Arab Emirates. And more.